As Ildong’s Belviq, which dominated the obese drug market for a long time, is finally exiting the market, there is a growing interest in which drug will fill this gap.

Obesity experts are predicting that safety-oriented prescriptions may be available for the time being, while Saxenda and Qsymia are expected to benefit directly.

The Ministry of Food and Drug Safety recently decided to stop selling and recall Belviq(lorcacerin) because of the risk of cancer. The U.S. Food and Drug Administration (FDA) has recommended its recovery, saying the risk is greater than the benefit.

As a result, Eisai in charge of the U.S. sales, immediately took over its own collection, and Ildong,